Kyowa Kirin Reclaims Rocatinlimab for Atopic Dermatitis

Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.

Published on Jan. 30, 2026

Got story updates? Submit your updates here. ›

Kyowa Kirin, a Japan-based global specialty pharmaceutical company, has announced the termination of its current rocatinlimab development and commercialization collaboration with Amgen. Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization. Rocatinlimab is an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells, showing potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD). Kyowa Kirin is confident in the potential of rocatinlimab to address critical unmet needs for patients with msAD and plans to file for regulatory approval in the U.S. first, followed by Japan, before expanding to other markets.

Why it matters

Atopic dermatitis is a chronic, inflammatory skin condition that can have a significant impact on a patient's quality of life. Rocatinlimab's novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor could provide a new, long-lasting treatment option for patients with moderate-to-severe atopic dermatitis who have not found relief with existing therapies.

The details

Rocatinlimab's Phase 3 ROCKET program, which consists of eight pivotal studies evaluating both long-term efficacy and safety, has demonstrated positive results. The program includes diverse patient populations, including adults and adolescents, systemic treatment-naïve patients, as well as those previously treated with biologics and JAK inhibitors, underscoring its potential as a meaningful treatment option for people living with atopic dermatitis across a broad range of clinical scenarios.

  • In November 2025, landmark findings from the Phase 3 ROCKET-IGNITE and ROCKET-HORIZON studies in nearly 1,500 adults with msAD were published in The Lancet.
  • Previously announced topline results from the primary analysis of the long-term safety extension study ROCKET-ASCEND demonstrated the potential for long-term therapeutic effect and extended dosing.

The players

Kyowa Kirin

A Japan-based global specialty pharmaceutical company that will regain control of the global rocatinlimab program, including regulatory filings and future commercialization.

Amgen

A company that has partnered with Kyowa Kirin on numerous investigational therapies over 41 years and will continue to manufacture rocatinlimab.

Abdul Mullick, Ph.D.

The President and Chief Operating Officer of Kyowa Kirin.

Takeyoshi Yamashita, Ph.D.

The Executive Vice President and Chief Medical Officer of Kyowa Kirin.

Got photos? Submit your photos here. ›

What they’re saying

“Kyowa Kirin is confident in the potential of rocatinlimab to address critical unmet needs for patients with moderate-to-severe atopic dermatitis who are looking for new, long-lasting options that may address the chronic nature of unpredictable flares.”

— Abdul Mullick, Ph.D., President and Chief Operating Officer of Kyowa Kirin (Kyowa Kirin)

“Based on the data available to-date, rocatinlimab has demonstrated a generally favorable benefit-risk profile across its Phase 3 clinical program, in which more than 3,300 patients with moderate to severe atopic dermatitis have been enrolled.”

— Takeyoshi Yamashita, Ph.D., Executive Vice President and Chief Medical Officer of Kyowa Kirin (Kyowa Kirin)

What’s next

The company plans to file for regulatory approval in the U.S. first, followed by Japan, before expanding to other markets across the world as appropriate.

The takeaway

Rocatinlimab's novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor could provide a much-needed new treatment option for patients with moderate-to-severe atopic dermatitis who have not found relief with existing therapies, potentially offering long-term disease control.